Menlo Security Joins VMware SD-WAN Security Technology Partner Program to Deliver Secure Cloud Transformation
6.11.2019 11:00:00 EET | Business Wire | Press release
Menlo Security, a leader in cloud security, today announced a new integration with VMware SD-WAN by VeloCloud, which offers the industry’s most flexible enterprise SD-WAN architecture. The solution delivers Secure Cloud Transformation, which optimizes and secures local Internet breakouts and enables global low latency access to the Internet and business-critical SaaS applications for an enterprise’s entire local and remote workforce. The integration is available immediately to all VMware SD-WAN customers.
“Menlo Security helps some of the largest enterprises and government agencies in the world transform their infrastructure and move security to the cloud, while maintaining global visibility and control of their traffic,” said Poornima DeBolle, chief product officer at Menlo Security. “VMware SD-WAN by VeloCloud combined with the Menlo Security Cloud Platform powered by isolation redefines security and provides the industry’s most secure solution for Internet and SaaS applications.”
"VMware SD-WAN provides the optimal combination of intrinsic security in the multi-service Edge for corporate traffic as well as SD-WAN optimized access via our Network of Clouds Service gateways to the innovative Menlo Security Cloud Platform powered by isolation," said Steve Woo, senior director of product management at VMware. "Access to cloud and SaaS applications is automatically provisioned, optimized for performance and secured with VMware SD-WAN and Menlo Security Cloud Platform."
VMware SD-WAN customers have simplified their branch office networking and optimized application performance over the Internet. Secure Cloud Transformation, powered by isolation, allows companies to improve security control and visibility across their SD-WAN deployment. Moving to SD-WAN requires an enterprise to move their security to the cloud since user traffic is not backhauled to a central security stack. Menlo Security Cloud Platform allows users to go directly to the Internet while ensuring consistent and robust security controls, whether they are connecting from HQ, remote offices, on the road or in a coffee shop.
Menlo Security’s customers include some of the largest enterprises and government agencies. The company’s cloud security platform currently processes more than 500 million web requests per day. Among the company’s customers are seven of the 10 largest banks, four of the five largest credit-card issuers and some of the largest energy and transportation companies in the world.
For more information, please send an email to ask@menlosecurity.com.
Additional Resources
- Secure Cloud Transformation
- Menlo Security Secure Web Gateway
- Definitive Guide to Internet Isolation
VMware and SD-WAN by VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
About Menlo Security
Menlo Security protects organizations from cyber attacks by eliminating the threat of malware from the web, documents and email. Its cloud-based Isolation Secure Web Gateway scales to provide comprehensive protection across enterprises of any size, without requiring endpoint software or impacting the end user-experience. The company was named a Visionary in the Gartner Magic Quadrant for the Secure Web Gateway. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC and JP Morgan Chase. Menlo Security is headquartered in Palo Alto, California. For more information, visit https://www.menlosecurity.com or ask@menlosecurity.com
VMware, and VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005218/en/
Contact information
Lexie Janney
Merritt Group for Menlo Security
703.390.1531
janney@merrittgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom